A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90-MX-DTPA-CT8466) COMBINED WITH

放射免疫治疗 (Y-90-MX-DTPA-CT8466) 结合的 I 期试验

• 批准号: 7716659
• 负责人: JEFFREY Y WONG
• 金额: $ 0.36万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716659
• 关键词: 90Y; Anti-CEA Antibody; Carboplatin/Paclitaxel; Cells; Computer Retrieval of Information on Scientific Projects Database; External Beam Radiation Therapy; Funding; Grant; Institution; Malignant neoplasm of lung; Maximum Tolerated Dose; Patients; Phase I Clinical Trials; Radioimmunotherapy; Research; Research Personnel; Resources; Source; Standards of Weights and Measures; Treatment Protocols; United States National Institutes of Health; Unresectable; chemotherapy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I trial evaluating the addition of radioimmunotherapy delivered as a single cycle of Yttrium-90 chimeric T84.66 anti CEA antibody in combination with standard external beam radiation therapy and Carboplatin and Paclitaxel chemotherapy for patients with unresectable locally advanced non-small cell CEA-positive lung cancer. The objective of the study is to determine the maximum tolerated dose of RIT that can be combined with the standard chemoradiotherapy regimen.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项I期试验，评估了添加作为YTTrium-90嵌合T84.66抗CEA抗体的单个周期的放射免疫疗法，并与标准的外部束放射治疗以及脑甲磷脂蛋白和紫杉醇化学疗法结合使用，可用于局部局部晚期非细胞细胞CEA CEA CEA CEA cea cea cea-Posiver Lung cancer。该研究的目的是确定可以与标准化学放疗方案结合使用的最大耐受性RIT剂量。